Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26404379
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Cancers+(Basel)
2015 ; 7
(3
): 1758-84
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Targeting RTK Signaling Pathways in Cancer
#MMPMID26404379
Regad T
Cancers (Basel)
2015[Sep]; 7
(3
): 1758-84
PMID26404379
show ga
The RAS/MAP kinase and the RAS/PI3K/AKT pathways play a key role in the
regulation of proliferation, differentiation and survival. The induction of these
pathways depends on Receptor Tyrosine Kinases (RTKs) that are activated upon
ligand binding. In cancer, constitutive and aberrant activations of components of
those pathways result in increased proliferation, survival and metastasis. For
instance, mutations affecting RTKs, Ras, B-Raf, PI3K and AKT are common in
perpetuating the malignancy of several types of cancers and from different tissue
origins. Therefore, these signaling pathways became prime targets for cancer
therapy. This review aims to provide an overview about the most frequently
encountered mutations, the pathogenesis that results from such mutations and the
known therapeutic strategies developed to counteract their aberrant functions.